Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Objectives Antimitochondrial antibodies (AMA) are a sensitive and specific marker for primary biliary cirrhosis (PBC). AMAs are present in 95% of patients with PBC. However, 5% do not have AMAs and data on these patients is scarce. We aim to evaluate the long-term outcomes of patients with AMA negative PBC. Methods A retrospective chart review of 71 AMA negative PBC patients. Disease presentation, laboratory results, and clinical endpoints were recorded. AMA negative patients were matched on year of diagnosis to a control group of 71 AMA positive patients. Results Ninety-six percent of the AMA negative patients were of female gender with a median age at diagnosis of 55 years and a length of follow-up of 7.5 years vs. 86% females, a median age of 56 and a follow-up of 8.3 years in the control group. Mean total bilirubin and alkaline phosphatase levels were 0.7 mg/dL vs. 0.6 and 570 U/L vs 341, in AMA negative vs. AMA positive patients at presentation, respectively (p = NS). AMA negative patients did not differ in terms of age, serum IgM levels, ANA status, or length of follow-up. Notably, AMA negative patients had a significantly reduced survival free of liver-related complications including transplantation and death compared to AMA positive patients (p = 0.0182). Conclusion In this large experience, AMA negative PBC patients had a significantly worse prognosis compared to AMA positive PBC patients. The reason for the difference in prognosis is unclear, as it may be true diffe…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, treatment response to UDCA appears similar in AMA-negative and AMA-positive PBC patients, and whether there are differences in clinical outcomes has not been resolved.(113,115)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [115]
In the citing paper
“Compared with AMA-positive PBC patients, AMAnegative PBC patients have more nonhepatic autoimmune conditions (114)(115) and worse health-related quality of life in social and emotional domains.(116)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [114]
In the citing paper
“Compared with AMA-positive PBC patients, AMAnegative PBC patients have more nonhepatic autoimmune conditions (114)(115) and worse health-related quality of life in social and emotional domains.(116)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [115]
Citations
Cites
(2012) · Hepatogastroenterology · doi:10.5754/hge12281 · Cited by 2,097
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationNakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365 · cited 1×
“Anti-Sp100 and anti-gp210 are PBC specific ANAs that have been associated with a more progressive disease.[25,26] Kinoshita et al.”
BackgroundInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293 · cited 4×
“Furthermore, they found no difference in biochemical response to UDCA.”
BackgroundInfluentialMichieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236 · cited 6×
“reported on 20 patients negative by IF of whom 17 were negative by blotting and ELISA.[9] Oertalt et al.”
BackgroundInfluentialMiyakawa, H., Tanaka, A., Kikuchi, K., Matsushita, M., Kitazawa, E., Kawaguchi, N., Fujikawa, H., & Gershwin, E. M. (2001) · Hepatology · doi:10.1053/jhep.2001.26514 · Cited by 200
Antimitochondrial antibody-negative primary biliary cirrhosis.
Lacerda, M. A., Ludwig, J., Dickson, E. R., Jorgensen, R. A., & Lindor, K. (1995) · PubMed · Cited by 196
Self-citationOertelt, S., Rieger, R., Selmi, C., Invernizzi, P., Ansari, A. A., Coppel, R. L., Podda, M., Leung, P. S. C., & Gershwin, E. M. (2007) · Hepatology · doi:10.1002/hep.21583 · Cited by 168
ter Borg, P. C. J., Schalm, S. W., Hansen, B. E., & van Buuren, H. R. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00699.x · Cited by 160
Research works printed but not linked: 3
- Lacerda MA, 1995, Am J Gastroenterol, 90, 247
- Tsou Y-K, 2003, Chang Gung Med J, 26, 323
- Zhang F-K, 2004, Hepatobiliary Pancreat Dis Int, 3, 288
Cited by
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationLleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Antimitochondrial Antibodies: from Bench to Bedside
Colapietro, F., Lleò, A., & Generali, E. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08904-y · Cited by 95
John, B. V., Schwartz, K., Levy, C., Dahman, B., Deng, Y., Martin, P., Taddei, T. H., & Kaplan, D. E. (2021) · Hepatology Communications · doi:10.1002/hep4.1720 · Cited by 51
Metadata
- Authors
- Juliusson, G., Imam, M., Björnsson, E. S., Talwalkar, J. A., & Lindor, K. D.
- Affiliations
- University of Iceland (IS)
- Mayo Clinic (US)
- Arizona State University (US)
- Corresponding author
- Talwalkar, Jayant A.
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2016-01-18
- Volume
- 51
- Issue
- 6
- Pages
- 745-752
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2290429686
- Cited by
- 47
- References
- 36
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 1
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Scandinavian Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, antimitochondrial antibodies, long-term outcomes, prognosis, survival, liver transplantation, liver-related mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Autoantibodies, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Mitochondria, Prognosis, Retrospective Studies, Biomarkers, Case-Control Studies, Liver Transplantation, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. https://app.cochat.ai/papers/10.3109/00365521.2015.1132337
- The paper
- Juliusson, G., Imam, M., Björnsson, E. S., Talwalkar, J. A., & Lindor, K. D. (2016). Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scandinavian Journal of Gastroenterology. https://doi.org/10.3109/00365521.2015.1132337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.